The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms
Abstract
Cancer clinical trials have relied on overall survival and measures of tumor growth or reduction to assess the efficacy of a drug. However, benefits are often accompanied by significant symptomatic toxicities. The degree to which a therapy improves disease symptoms and introduces symptomatic toxicity affects how patients function in their daily lives. These concepts are important contributors to health-related quality of life (HRQOL). In this article, we discuss patient-reported outcome (PRO) assessment in cancer trials and challenges relying solely on static multi-item HRQOL instruments. We propose focusing on three separate measures of well-defined concepts: symptomatic adverse events, physical function, and disease-related symptoms, which are key contributors to the effect of a therapy on HRQOL. Separate measures of these three concepts may facilitate the incorporation of emerging contemporary instruments that can tailor the PRO assessment strategy to different trial contexts. Irrespective of the PRO measures used, continued improvement in trial design and conduct is crucial to decrease missing data and optimize the quality of PRO information. International stakeholder collaboration and continued research into optimal practices for PRO and other clinical outcome assessments are necessary to advance a common framework for generating and reporting rigorous patient-centered data from cancer clinical trials. Clin Cancer Res; 22(7); 1553–8. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Assessing symptom distress in cancer patients: The M. D. Anderson Symptom Inventory
Cleeland, C. S., Mendoza, T. R., Wang, X. S., Chou, C., Harle, M. T., Morrissey, M., & Engstrom, M. C. (2000) · Cancer · doi:10.1002/1097-0142(20001001)89:7<1634::aid-cncr29>3.0.co;2-v · Cited by 1,360
Basch, E., Reeve, B. B., Mitchell, S. A., Clauser, S. B., Minasian, L. M., Dueck, A. C., Mendoza, T. R., Hay, J., Atkinson, T. M., Abernethy, A. P., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju244 · Cited by 1,151
Dueck, A. C., Mendoza, T. R., Mitchell, S. A., Reeve, B. B., Castro, K. M., Rogak, L. J., Atkinson, T. M., Bennett, A. V., Denicoff, A. M., O'Mara, A. M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2639 · Cited by 1,030
Performance status assessment in cancer patients. An inter-observer variability study
Sørensen, J., Klee, M., Palshof, T., & Hansen, H. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.140 · Cited by 483
Rose, M., Bjorner, J. B., Gandek, B., Bruce, B., Fries, J. F., & Ware, J. E. (2014) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.10.024 · Cited by 442
Recommended Patient-Reported Core Set of Symptoms to Measure in Adult Cancer Treatment Trials
Reeve, B. B., Mitchell, S. A., Dueck, A. C., Basch, E., Cella, D., Reilly, C. M., Minasian, L. M., Denicoff, A. M., O'Mara, A. M., Fisch, M. J., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju129 · Cited by 350
Assessing the Clinical Significance of Single Items Relative to Summated Scores
SLOAN, J. A., AARONSON, N., CAPPELLERI, J. C., FAIRCLOUGH, D. L., & VARRICCHIO, C. (2002) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)62218-0 · Cited by 256
Jensen, R. E., Potosky, A. L., Reeve, B. B., Hahn, E., Cella, D., Fries, J., Smith, A. W., Keegan, T. H. M., Wu, X.-C., Paddock, L., et al. (2015) · Quality of Life Research · doi:10.1007/s11136-015-0992-9 · Cited by 237
Cited by
Mercieca-Bebber, R., King, M. T., Calvert, M. J., Stockler, M. R., & Friedlander, M. (2018) · Patient Related Outcome Measures · doi:10.2147/prom.s156279 · Cited by 659
“36 Snyder et al describe how to develop a measurement strategy for prospective labeling claims.”
Kluetz, P. G., Chingos, D. T., Basch, E. M., & Mitchell, S. A. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159514 · Cited by 361
Self-citationBevans, M., El-Jawahri, A., Tierney, D. K., Wiener, L., Wood, W. A., Hoodin, F., Kent, E. E., Jacobsen, P. B., Lee, S. J., Hsieh, M. M., et al. (2017) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2016.09.011 · Cited by 166
Calvert, M., King, M., Mercieca-Bebber, R., Aiyegbusi, O., Kyte, D., Slade, A., Chan, A.-W., Basch, E., Bell, J., Bennett, A., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-045105 · Cited by 144
Fang, C., Markuzon, N., Patel, N., & Rueda, J.-D. (2022) · Value in Health · doi:10.1016/j.jval.2022.06.004 · Cited by 36
Metadata
- Authors
- Kluetz, P. G., Slagle, A., Papadopoulos, E. J., Johnson, L. L., Donoghue, M., Kwitkowski, V. E., Chen, W.-H., Sridhara, R., Farrell, A. T., Keegan, P., Kim, G., & Pazdur, R.
- Venue
- Clinical Cancer Research
- Published
- 2016-03-31
- Volume
- 22
- Issue
- 7
- Pages
- 1553-1558
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2238083898
- Cited by
- 334
- References
- 18
- FWCI
- 12.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-2035
- The paper
- Kluetz, P. G., Slagle, A., Papadopoulos, E. J., Johnson, L. L., Donoghue, M., Kwitkowski, V. E., Chen, W.-H., Sridhara, R., Farrell, A. T., Keegan, P., Kim, G., & Pazdur, R. (2016). Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-2035
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.